Results 71 to 80 of about 3,220 (195)

A quantitative systems pharmacology model for certolizumab pegol treatment in moderate-to-severe psoriasis

Frontiers in Immunology, 2023
BackgroundPsoriasis is a chronic immune-mediated inflammatory systemic disease with skin manifestations characterized by erythematous, scaly, itchy and/or painful plaques resulting from hyperproliferation of keratinocytes.
Pablo Coto-Segura, Cristina Segú-Vergés, Cristina Segú-Vergés, Antonio Martorell, David Moreno-Ramírez, Guillem Jorba, Guillem Jorba, Valentin Junet, Valentin Junet, Filippo Guerri, Filippo Guerri, Xavier Daura, Xavier Daura, Xavier Daura, Baldomero Oliva, Carlos Cara, Olaya Suárez-Magdalena, Sonya Abraham, Sonya Abraham, José Manuel Mas   +19 more
doaj   +1 more source

Complex Mixtures: Array PBPK Modeling of Jet Fuel Components

Toxics, 2023
An array physiologically-based pharmacokinetic (PBPK) model represents a streamlined method to simultaneously quantify dosimetry of multiple compounds. To predict internal dosimetry of jet fuel components simultaneously, an array PBPK model was coded to simulate inhalation exposures to one or more selected compounds: toluene, ethylbenzene, xylenes, n ...
Teresa R. Sterner, Tammie R. Covington, David R. Mattie   +2 more
openaire   +3 more sources

Cardiovascular‐Kidney‐Metabolic Syndrome in People With HIV: An Emerging Frontier for Clinical Pharmacology

Clinical Pharmacology &Therapeutics, EarlyView.
As antiretroviral therapy (ART) prolongs lifespans, people with HIV (PWH) face a new syndemic: Cardiovascular‐Kidney‐Metabolic (CKM) syndrome. Yet CKM in PWH is poorly characterized. Inflammation, complex pharmacokinetic (PK) alterations, ART‐associated metabolic effects, and gut dysbiosis amplify risk. Managing CKM increases medication burden, thereby
Aaron S. Devanathan, Thomas D. Nolin
wiley   +1 more source

Safety and feasibility trial protocol of metformin in infants after perinatal brain injury

BMJ Paediatrics Open
Introduction Infants with hypoxic-ischaemic encephalopathy (HIE) are at a high risk for neurodevelopmental impairment, and adjunctive treatments to promote brain repair are needed.
Martin Offringa, Tamorah Lewis, Anne-Marie Hutchinson, Rosanna Pais, Andrea N Endginton, Betsy Pilon, Jordan M MacDonald, Mallory E MacDonald, Brian Thomas Kalish   +8 more
doaj   +1 more source

Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach [PDF]

, 2012
Developmental neurotoxicity (DNT) and many forms of reproductive toxicity (RT) often manifest themselves in functional deficits that are not necessarily based on cell death, but rather on minor changes relating to cell differentiation or communication ...
Agapios Sachinidis, Andreas Kortenkamp, Anne K. Krug, Christoph van Thriel, Daniel Gerhard, Dimitra Zagoura, Eugen Rempel, Hedi Peterson, Isaia Sotiriadou, Jaak Vilo, Jan G. Hengstler, Johannes Winkler, John A. Gaspar, Joost Westerhout, Jörg Rahnenführer, Jürgen Hescheler, Karl-Heinz Krause, Karthick Natarajan, Kesavan Meganathan, Kinga Vojnits, Luc Stoppini, Ludwig Hothorn, Marcel Leist, Margit Henry, Mathurin Baquié, Michael Heke, Miriam Verwei, Nina V. Balmer, Raivo Kolde, Richard M. Evans, Roberto Ensenat-Waser, Rosemarie Marchan, Sieto Bosgra, Smita Jagtap, Stephanie Julien, Susanne Bremer, Suzanne Kadereit, Tanja Waldmann   +37 more
core   +3 more sources

Building Pharmacoequity through Student and Trainee Education, Service, and Global Outreach

Clinical Pharmacology &Therapeutics, EarlyView.
Students and trainees are integral to clinical pharmacology, as they have the potential to shape the field. This perspective highlights how the ASCPT Student and Trainee Community engages members worldwide, providing opportunities and resources to advance scientific and professional development.
Chazmyn Riley, Natasha Desiree Casas, Patricia D. Maglalang, Hongyu Su, An Le, Shravani Etrouth, Shayna R. Killam, MaryPeace McRae   +7 more
wiley   +1 more source

Pharmacokinetic-Pharmacodynamic Modeling in Pediatric Drug Development, and the Importance of Standardized Scaling of Clearance. [PDF]

, 2018
Pharmacokinetic/pharmacodynamic (PKPD) modeling is important in the design and conduct of clinical pharmacology research in children. During drug development, PKPD modeling and simulation should underpin rational trial design and facilitate extrapolation
A Cram, A Hooker, A Rao, AA Vinks, AH Thomson, AK Done, AM Johansson, AN Edginton, AN Edginton, AR Maharaj, AR Maharaj, B Green, B Quijano Ruiz, BJ Anderson, BJ Anderson, C Stockmann, CA Knibbe, CC Peck, CF Weiss, Charlotte I. S. Barker, CI Barker, CIS Barker, D Lin, DB Hawcutt, DJ Eleveld, E Germovsek, E Germovsek, E Germovsek, E Kimland, E Manolis, E Manolis, EI Ette, EI Ette, Eva Germovsek, F Rodieux, FG Benedict, G Langdon, G Nellis, GEP Box, GJ Robbie, GL Kearns, H Kimko, H Mulla, H Padari, H Shirkey, HG Eichler, HM Jones, HS Al-Sallami, I Adatia, I Bains, I Mahmood, I Mahmood, I Mahmood, IH Bartelink, J Alcorn, J Dunne, J Gillis, J Lerman, J Nyberg, J Nyberg, JA Roberts, JD Crawford, JE Sager, JF Standing, JF Standing, JF Standing, JK Roberts, JM Nicolas, Joseph F. Standing, JR Bellis, JS Barrett, JS Barrett, JS Barrett, JT Gilman, K Kipper, KD Wittmeier, KL Brouwer, L Aarons, L Cuzzolin, L Harnisch, L Harnisch, LE Kelly, LV Hampson, M Cella, M Cella, M Cella, M Danhof, M Jamei, M Kleiber, M Kleiber, M Minocha, M Neely, M Pfister, M Rowland, MA Montenegro, MA Turner, MA Turner, MA Turner, MA Turner, Mike Sharland, ML Christensen, MM Rhodin, MO Karlsson, MY Peeters, N Holford, N Kleiber, N Modi, NH Holford, P Espie, PA Valitalo, PD Joseph, PH Graaf van der, RE Kauffman, RF Cock De, RM Ward, RM Ward, RS Kadam, RW Jelliffe, S Conroy, S Duffull, S Feng, S Hennig, S Hennig, S Kanoh, S Leroux, SC McLeay, SE Tett, SG Wicha, SM MacLeod, SW Briggs, T Schechter, TA Leil, TA Leil, TH Nguyen, TN Johnson, TN Johnson, TN Johnson, TP Klassen, TS Samant, V Ramos-Martin, VH Tam, W Knebel, W Van’t Hoff, W Zhao, WA Silverman, Y Wang   +145 more
core   +2 more sources

An IQ Consortium Perspective on the FDA Guidance for Assessment of Pharmacokinetics in Participants With Impaired Renal Function

Clinical Pharmacology &Therapeutics, EarlyView.
The FDA published guidance on assessing pharmacokinetics (PK) in participants with impaired renal function in 2024. The IQ CPLG Organ Impairment Working Group summarized the industry’s perspective on this guidance by highlighting a few key updates in the 2024 guidance, including: (1) the recommendation of using estimated glomerular filtration rate ...
Yan Jin, Ashish Sharma, Mariam A. Ahmed, Sravanthi Cheeti, Ying Ou, Damayanthi Devineni, Yizhe Chen, Jitendra S. Kanodia, Yasmeen Abouelhassan, Nadia Noormohamed, Jin Zhou, Patrick Marroum, Vaishali Sahasrabudhe, Islam R. Younis   +13 more
wiley   +1 more source

Formulation development, in vivo bioequivalence and pediatric PBPK modeling studies of taste-masked ciprofloxacin chewable tablets

Scientific Reports, 2023
A taste-masked chewable tablet of ciprofloxacin using ion exchange resin Kyron T-134 for enhancing compliance for the paediatric population was developed.
Muhammad Talha Usmani, Muhammad Harris Shoaib, Fahad Siddiqui, Farrukh Rafiq Ahmed, Rabia Ismail Yousuf, Muhammad Talha Saleem   +5 more
doaj   +1 more source

Addressing human variability in next-generation human health risk assessments of environmental chemicals [PDF]

, 2012
International audienceCharacterizing variability in the extent and nature of responses to environmental exposures is a critical aspect of human health risk assessment.
Beal SL, Chiu WA, Dale Hattis, Frederic Y. Bois, Ivan Rusyn, Kathryn Z. Guyton, Lauren Zeise, Weihsueh A. Chiu   +7 more
core   +4 more sources